Amgen (AMGN) 169.77 $AMGN Top Research Reports
Post# of 273257
Posted On: 09/03/2016 7:14:04 PM
Amgen (AMGN) 169.77 $AMGN
Top Research Reports for September 2, 2016
Sheraz Mian - Zacks Investment Research - Fri Sep 02, 10:33AM CDT
Top Research Reports for September 2, 2016
AMGN: 169.77 (-0.36), CPB: 57.73 (+0.82), HSBC: 38.65 (+0.77), INFY: 16.30 (+0.20), AVGO: 173.11 (-3.98), NVDA: 62.53 (-0.62)
Amgen Gets FDA Approval for Label Expansion of Blincyto
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 7:45AM CDT
Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion for its leukemia immunotherapy Blincyto.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
FDA Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
PR Newswire - Thu Sep 01, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials.
AMGN: 169.77 (-0.36)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), MYL: 39.97 (-1.95), AMGN: 169.77 (-0.36), ARIA: 10.12 (-0.07), RIGL: 3.40 (-0.05), REGN: 388.64 (-4.76)
Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgen's Enbrel
ACCESSWIRE - Thu Sep 01, 8:15AM CDT
LONDON, UK / ACCESSWIRE / September 1, 2016 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS). On August 30, 2016, the US Food and Drug Administration (FDA) approved Novartis AG's drug Erelzi which is a biosimilar to Amgen Inc.'s (NASDAQ: AMGN) Enbrel. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
JNJ: 119.32 (+0.24), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), NVS: 79.38 (+1.11)
Amgen Obtains Global Development And Commercial Rights From Boehringer Ingelheim For Investigational BiTE® Immuno-Oncology Drug For Multiple Myeloma
PR Newswire - Thu Sep 01, 8:00AM CDT
Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma. BI 836908 (AMG 420) is currently in Phase 1 studies. BI 836908 (AMG 420) was originally licensed to Boehringer Ingelheim by Micromet before the company was acquired by Amgen in 2012.
AMGN: 169.77 (-0.36)
Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development
GlobeNewswire - Thu Sep 01, 7:30AM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) today announced the advancement of omecamtiv mecarbil to Phase 3 clinical development with a cardiovascular outcomes clinical trial expected to initiate in the fourth quarter of 2016. Omecamtiv mecarbil, a novel investigational cardiac myosin activator, enhances cardiac function by increasing cardiac contractility and is being developed for the potential treatment of patients with chronic heart failure.
CYTK: 10.36 (-0.14), AMGN: 169.77 (-0.36)
Amgen And Servier Extend Omecamtiv Mecarbil Collaboration In Chronic Heart Failure
PR Newswire - Thu Sep 01, 7:30AM CDT
Amgen (NASDAQ:AMGN) and Servier today announced an advancement in their cardiovascular collaboration, with Servier's decision to exercise its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe, as well in as the Commonwealth of Independent States, including Russia, which were added to the collaboration. The companies also announced the omecamtiv mecarbil Phase 3 development program will move forward in collaboration with Cytokinetics.
AMGN: 169.77 (-0.36)
The Medicines Co. Offers Update on Dyslipidemia Programs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:13AM CDT
The Medicines Company (MDCO) provided an update on its dyslipidemia programs - MDCO-216 and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 38.31 (-0.66), AMGN: 169.77 (-0.36), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:59AM CDT
Novartis (NVS) received a major boost when its generic arm, Sandoz obtained FDA approval for Erelzi, the biosimilar version of Amgen???s blockbuster drug Enbrel (etanercept).
PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), NVS: 79.38 (+1.11)
Novartis wins US OK for biosimilar version of Amgen's Enbrel
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Tue Aug 30, 5:29PM CDT
U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.
JNJ: 119.32 (+0.24), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36)
Pulse Biosciences Appoints Holly Hartman as Vice President of Business Development and Corporate Strategy
BusinessWire - Tue Aug 30, 3:00PM CDT
Pulse Biosciences, Inc., (NASDAQ: PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Electro-Signaling, today announced that it has appointed Holly Hartman, Ph.D., J.D., as its Vice President, Business Development and Corporate Strategy.
AMGN: 169.77 (-0.36), PLSE: 5.00 (+0.01)
These Stocks are Predicted to Outperform this Week According to Forcerank
ESTMZ - Tue Aug 30, 2:30PM CDT
Each week Forcerank runs a variety of games covering different industries. What we have found, is that the highest ranked companies in their respective games deliver the greatest positive price movement for that week. This week, the winners include...
UA: 38.56 (-1.19), DVN: 44.27 (+0.57), AMZN: 772.44 (+1.82), SPY: 218.37 (+0.98), NKE: 58.02 (-0.52), FB: 126.51 (+0.34), AMGN: 169.77 (-0.36), AAPL: 107.73 (+1.00)
Amgen (AMGN) Reports Positive Data on Prolia and Repatha
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:03AM CDT
Amgen announced positive data on Prolia and Repatha from late stage studies.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Global Interleukin 15 (IL15) Pipeline Review 2016 Featuring Amgen, Calypso Biotech & Digna Biotech - Research and Markets
BusinessWire - Mon Aug 29, 1:07PM CDT
Research and Markets has announced the addition of the "Interleukin 15 (IL15) - Pipeline Review, H1 2016" report to their offering.
AMGN: 169.77 (-0.36)
Regeneron/Sanofi Present Positive Phase III Praluent Data
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:33AM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy
PR Newswire - Mon Aug 29, 8:00AM CDT
Amgen (NASDAQ: AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. The study met all primary and secondary endpoints at 12 months. The data showed that treatment with Prolia for 12 months, compared to risedronate, led to significantly greater gains in bone mineral density (BMD) at the lumbar spine and total hip, both in patients receiving continuing glucocorticoid therapy and in patients newly initiating glucocorticoid therapy.
AMGN: 169.77 (-0.36)
New Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016
PR Newswire - Mon Aug 29, 1:00AM CDT
Amgen (NASDAQ:AMGN) today announced data presented at the European Society of Cardiology (ESC) Congress 2016 showing Repatha® (evolocumab) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients across cardiovascular (CV) risk subgroups or with familial hypercholesterolemia (FH).
AMGN: 169.77 (-0.36)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 45.80 (-0.54), MRK: 62.98 (+0.08), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28)
Amgen Gets CRL for Secondary Hyperparathyroidism Drug
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:28AM CDT
Amgen (AMGN) announced that the FDA has issued a Complete Response Letter from for its New Drug Application (NDA) for Parsabiv.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Top Research Reports for September 2, 2016
Sheraz Mian - Zacks Investment Research - Fri Sep 02, 10:33AM CDT
Top Research Reports for September 2, 2016
AMGN: 169.77 (-0.36), CPB: 57.73 (+0.82), HSBC: 38.65 (+0.77), INFY: 16.30 (+0.20), AVGO: 173.11 (-3.98), NVDA: 62.53 (-0.62)
Amgen Gets FDA Approval for Label Expansion of Blincyto
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 7:45AM CDT
Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion for its leukemia immunotherapy Blincyto.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
FDA Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
PR Newswire - Thu Sep 01, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials.
AMGN: 169.77 (-0.36)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), MYL: 39.97 (-1.95), AMGN: 169.77 (-0.36), ARIA: 10.12 (-0.07), RIGL: 3.40 (-0.05), REGN: 388.64 (-4.76)
Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgen's Enbrel
ACCESSWIRE - Thu Sep 01, 8:15AM CDT
LONDON, UK / ACCESSWIRE / September 1, 2016 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS). On August 30, 2016, the US Food and Drug Administration (FDA) approved Novartis AG's drug Erelzi which is a biosimilar to Amgen Inc.'s (NASDAQ: AMGN) Enbrel. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
JNJ: 119.32 (+0.24), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), NVS: 79.38 (+1.11)
Amgen Obtains Global Development And Commercial Rights From Boehringer Ingelheim For Investigational BiTE® Immuno-Oncology Drug For Multiple Myeloma
PR Newswire - Thu Sep 01, 8:00AM CDT
Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma. BI 836908 (AMG 420) is currently in Phase 1 studies. BI 836908 (AMG 420) was originally licensed to Boehringer Ingelheim by Micromet before the company was acquired by Amgen in 2012.
AMGN: 169.77 (-0.36)
Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development
GlobeNewswire - Thu Sep 01, 7:30AM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) today announced the advancement of omecamtiv mecarbil to Phase 3 clinical development with a cardiovascular outcomes clinical trial expected to initiate in the fourth quarter of 2016. Omecamtiv mecarbil, a novel investigational cardiac myosin activator, enhances cardiac function by increasing cardiac contractility and is being developed for the potential treatment of patients with chronic heart failure.
CYTK: 10.36 (-0.14), AMGN: 169.77 (-0.36)
Amgen And Servier Extend Omecamtiv Mecarbil Collaboration In Chronic Heart Failure
PR Newswire - Thu Sep 01, 7:30AM CDT
Amgen (NASDAQ:AMGN) and Servier today announced an advancement in their cardiovascular collaboration, with Servier's decision to exercise its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe, as well in as the Commonwealth of Independent States, including Russia, which were added to the collaboration. The companies also announced the omecamtiv mecarbil Phase 3 development program will move forward in collaboration with Cytokinetics.
AMGN: 169.77 (-0.36)
The Medicines Co. Offers Update on Dyslipidemia Programs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:13AM CDT
The Medicines Company (MDCO) provided an update on its dyslipidemia programs - MDCO-216 and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 38.31 (-0.66), AMGN: 169.77 (-0.36), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:59AM CDT
Novartis (NVS) received a major boost when its generic arm, Sandoz obtained FDA approval for Erelzi, the biosimilar version of Amgen???s blockbuster drug Enbrel (etanercept).
PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), NVS: 79.38 (+1.11)
Novartis wins US OK for biosimilar version of Amgen's Enbrel
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Tue Aug 30, 5:29PM CDT
U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.
JNJ: 119.32 (+0.24), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36)
Pulse Biosciences Appoints Holly Hartman as Vice President of Business Development and Corporate Strategy
BusinessWire - Tue Aug 30, 3:00PM CDT
Pulse Biosciences, Inc., (NASDAQ: PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Electro-Signaling, today announced that it has appointed Holly Hartman, Ph.D., J.D., as its Vice President, Business Development and Corporate Strategy.
AMGN: 169.77 (-0.36), PLSE: 5.00 (+0.01)
These Stocks are Predicted to Outperform this Week According to Forcerank
ESTMZ - Tue Aug 30, 2:30PM CDT
Each week Forcerank runs a variety of games covering different industries. What we have found, is that the highest ranked companies in their respective games deliver the greatest positive price movement for that week. This week, the winners include...
UA: 38.56 (-1.19), DVN: 44.27 (+0.57), AMZN: 772.44 (+1.82), SPY: 218.37 (+0.98), NKE: 58.02 (-0.52), FB: 126.51 (+0.34), AMGN: 169.77 (-0.36), AAPL: 107.73 (+1.00)
Amgen (AMGN) Reports Positive Data on Prolia and Repatha
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:03AM CDT
Amgen announced positive data on Prolia and Repatha from late stage studies.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Global Interleukin 15 (IL15) Pipeline Review 2016 Featuring Amgen, Calypso Biotech & Digna Biotech - Research and Markets
BusinessWire - Mon Aug 29, 1:07PM CDT
Research and Markets has announced the addition of the "Interleukin 15 (IL15) - Pipeline Review, H1 2016" report to their offering.
AMGN: 169.77 (-0.36)
Regeneron/Sanofi Present Positive Phase III Praluent Data
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:33AM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy
PR Newswire - Mon Aug 29, 8:00AM CDT
Amgen (NASDAQ: AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. The study met all primary and secondary endpoints at 12 months. The data showed that treatment with Prolia for 12 months, compared to risedronate, led to significantly greater gains in bone mineral density (BMD) at the lumbar spine and total hip, both in patients receiving continuing glucocorticoid therapy and in patients newly initiating glucocorticoid therapy.
AMGN: 169.77 (-0.36)
New Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016
PR Newswire - Mon Aug 29, 1:00AM CDT
Amgen (NASDAQ:AMGN) today announced data presented at the European Society of Cardiology (ESC) Congress 2016 showing Repatha® (evolocumab) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients across cardiovascular (CV) risk subgroups or with familial hypercholesterolemia (FH).
AMGN: 169.77 (-0.36)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 45.80 (-0.54), MRK: 62.98 (+0.08), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28)
Amgen Gets CRL for Secondary Hyperparathyroidism Drug
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:28AM CDT
Amgen (AMGN) announced that the FDA has issued a Complete Response Letter from for its New Drug Application (NDA) for Parsabiv.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
(0)
(0)Scroll down for more posts ▼